Development of macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients treated with macrolides.
Nilsson, Anna LU ; Jensen, Jørgen Skov ; Björkman, Per LU
and Persson, Kenneth
LU
(2014)
In Scandinavian Journal of Infectious Diseases
46(4).
p.315-319
- Abstract
- Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment. Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation. Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest... (More)
- Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment. Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation. Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest M. pneumoniae carriage time in these patients was 7 months and the longest symptomatic period was 7.5 months. Macrolide resistance was detected after macrolide treatment in 1 patient (carriage time 3.5 months and symptomatic period 7.5 months). Conclusions: M. pneumoniae may develop macrolide resistance during macrolide treatment. A long duration of M. pneumoniae carriage and symptoms is common in patients regardless of the presence of resistance. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4290954
- author
- Nilsson, Anna
LU
; Jensen, Jørgen Skov
; Björkman, Per
LU
and Persson, Kenneth
LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Infectious Diseases
- volume
- 46
- issue
- 4
- pages
- 315 - 319
- publisher
- Informa Healthcare
- external identifiers
-
- pmid:24447251
- wos:000333045600011
- scopus:84898939792
- ISSN
- 1651-1980
- DOI
- 10.3109/00365548.2013.866268
- language
- English
- LU publication?
- yes
- id
- 5b611edb-6761-4851-9c9c-452b291b62b5 (old id 4290954)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24447251?dopt=Abstract
- date added to LUP
- 2016-04-01 10:08:49
- date last changed
- 2022-04-27 18:58:57
@article{5b611edb-6761-4851-9c9c-452b291b62b5,
abstract = {{Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment. Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation. Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest M. pneumoniae carriage time in these patients was 7 months and the longest symptomatic period was 7.5 months. Macrolide resistance was detected after macrolide treatment in 1 patient (carriage time 3.5 months and symptomatic period 7.5 months). Conclusions: M. pneumoniae may develop macrolide resistance during macrolide treatment. A long duration of M. pneumoniae carriage and symptoms is common in patients regardless of the presence of resistance.}},
author = {{Nilsson, Anna and Jensen, Jørgen Skov and Björkman, Per and Persson, Kenneth}},
issn = {{1651-1980}},
language = {{eng}},
number = {{4}},
pages = {{315--319}},
publisher = {{Informa Healthcare}},
series = {{Scandinavian Journal of Infectious Diseases}},
title = {{Development of macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients treated with macrolides.}},
url = {{http://dx.doi.org/10.3109/00365548.2013.866268}},
doi = {{10.3109/00365548.2013.866268}},
volume = {{46}},
year = {{2014}},
}